Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration

Published on 02 Jan 2024
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to:

  • diabetic macular oedema; and

  • neovascular (wet) age-related macular degeneration.

Funding status

Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024.

MAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.

Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration (Published 2 Jan 2024) [PDF, 147 KB]

PES Aflibercept and faricimab for treating diabetic macular oedema and age-related macular degeneration (Published 2 Jan 2024) [PDF, 129 KB]